September 11, 2018 1:18pm
Q2/18 financial results also known as (AKA) earnings is a ‘scorecard’ of public stem, cell, gene therapies and editing, regenerative therapy and a couple of CNS and RNAi companies
Thirty-six (36) LPS, four (4) net income and two (2) delayed or incomplete - Intrexon (XON) and MiMedx (MDXG) ... so far of 45 covered companies
The current LPS (loss per share) standings reflect the universes’ investing status; then add in their cash position and "runways" for a better snapshot!
By analyzing these comparisons, investors can begin to gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.
| COMPANY | SYMBOL | NET INCOME | Q2/18 LOSS | Q2/18 LPS | Q2/18 CASH | RUNWAY |
|---|---|---|---|---|---|---|
| Aduro Biotech, Inc. | ADRO | -$24.4 M | -$0.31 | $305.9 M | 2020 | |
| Alnylam Pharmaceuticals | ALNY | -$163.6 M | -$1.63 | $1.46 B | N/A | |
| Applied Genetic Technologies | AGTC |
-$6.6 M -$21.3 M (FY18) |
-$0.37 -$1.18 |
$104.9 M | 2020 | |
| Asterias Biotherapeutics | AST | -$7.4 M | -$0.13 | $14.8 M | Q3/19 | |
| Athersys, Inc. | ATHX |
+$6.9 M or +$0.05 per share |
$53.4 M | 2020 | ||
| Adverum Biotechnologies, Inc. | ADVM | -$18.8 | -$0.30 | $574.19 M | 2020 | |
| Audentes Therapeutics | BOLD | -$31.4 M | -$0.85 | $314.4 M | Q2/20 | |
| AxoGen, Inc. | AXGN | -$7.4 M | -$0.20 | $133.6 M | 2021 | |
| Bellicum Pharmaceuticals, Inc. | BLCM | -$24.2 M | -$0.60 | $135.3 M | 2020 | |
| BioLife Solutions, Inc. | BLFS |
+$1 M or +0.05 per share |
$14.2 M | Q4/20 | ||
| BioMarin Pharmaceuticals | BMRN | -$16.8 M | -$1.09 | $1.6 B | N/A | |
| Biostage, Inc. | BSTG | -$2.1 M | -$0.55 | $5.8 M | Q1/19 | |
| BioTime, Inc. | BTX | -$4.2 M | -$0.03 |
$27.2 M $21.6 M $21.6 note |
2020 | |
| bluebird bio | BLUE | -$1.46 M | -$2.91 |
$1.46 B +$600 M |
2022 | |
| Brainstorm Cell Therapeutics Inc. | BCLI | -$3.1 M | -$0.16 | $17.4 M | Q4/19 | |
| Caladrius Biosciences. | CLBS | -$4.1 M | -$0.42 | $50.3 M | Q4/19 | |
| Cellectis SA | CLLS | -$7.38 M | -$0.17 |
$191 M $61 M |
2022 | |
| Cesca Therapeutics, Inc | KOOL | -$26.6 M | -$1.73 |
$3 M raised $5.5 M |
2019 | |
| CRISPR Therapeutics | CRSP | -$38.4 M | -$0.82 | $319.7 M | 2021 | |
| Editas Medicine | EDIT | -$38.7 M | -$0.82 | $344.1 M | 2022 | |
| Fate Therapeutics, Inc. | FATE | -$19.7 M | -$0.37 | $78 M | 2022 | |
| Global Blood Therapeutics | GBT | -$40.4 M | -$0.76 | $51.4 M | 2019 | |
| Histogenics Corporation | HSGX | -$3.7 M | -$0.13 | $8.8 M | Q4/18 | |
| Homology Medicine | FIXX | -$12.9 M | -$0.35 | $255.% M | Q2/20 | |
| Intellia Therapeutics | NTLA | -$22.2 M | -$0.52 | $305.5 M | 2020 | |
| Intrexon Corporation | XON |
DELAYED due to Q1/18 filing |
-$65.4 N (pre-lim) | -$0.51 | ?? | Not evident |
| Ionis Pharmaceuticals | IONS | -$56.6 M | -$0.29 | $2 B | N/A | |
| Mesoblast Limited | MESO | -$20.8 M | -$4.39 |
$37.8 M $39 M (debt) $40 M (Tasly) |
2020 | |
| MiMedx Group, Inc | MDXG |
Delayed Under Review |
||||
| Neuralstem, Inc. | CUR | -$627 K | -$0.04 | $7 M | Q1/19 | |
| Organovo Holdings, Inc. | ONVO | -$7.4 M | -$0.07 | $39.6 M | Q1/20 | |
| Osiris Therapeutics, Inc. | OSIR | -$2.67 M | -$0.07 | $32 M | Q1/20 | |
| Pluristem Therapeutics, Inc. | PSTI | -$1.5 M | -$0.01 | $33.3 M | 2019 | |
| ReNeuron Group PLC | RENE.L | Still missing | ||||
| Regenxbio | RGNX |
+$10.6 M or per share +$0.330 (D) +$0.33 (B) |
$306.3 M | 2021 | ||
| Sage Therapeutics | SAGE | -$17 M | -$0.36 | $1.1 B | 2020 | |
| Sangamo Biosciences, Inc. | SGMO | -$16.6 M | -$0.17 | $574.19 M | 2020 | |
| Solid Biosciences | SLDB | -$18 M | -$0.52 | $162.8 M | 2021 | |
| Spark Therapeutics, Inc. | ONCE |
+$80.2 M or +$2.15 per share |
$656.8 M | 2022 | ||
| Stemline Therapeutics, Inc. | STML | -$18.9 M | -$0.66 | $97.1 M | 2020 | |
| Ultragenyx | RARE | -$52.7 M | -$1.06 | $547.1 M | 2020 | |
| uniQure N.V. | QURE | -$20.6 M | -$0.57 | $259 M | 2021 | |
| Verastem, Inc. | VSTM | -$18.4 M | -$0.30 | $168.7 M | 2020 | |
| Vericel Corporation | VCEL | -$4.7 M | -$0.123 | $95 M | 2020 | |
| Voyager Therapeutics | VYGR | -$25.5 M | -$0.80 | $197 M | 2020 |
